Philadelphia, May 2 /PRNewswire/ — Leading provider of endpoint technologies for clinical trials is setting ambitious goals to reduce translation time by 20-30% by investing in new technologies and processes
Clario, ein Technologieunternehmen, das führende Endpunkttechnologielösungen für dezentralisierte (DCT), hybrid und standortbasierte klinische Studien anbietet, gab heute eine Investition in eine neue Über diemitzungsdienst – Worksettbewernt-Technolog 20 Should. This will reduce times for ramping up eCOA studies and improve patients’ access to clinical trials worldwide.
“Our clients need to conduct studies in multiple countries and ensure patients receive accurate and timely translations to evaluate their own electronic clinical outcomes. This is critical to a successful study,” said Andy Cooper, EVP eCOA & Trial Enablement, by Clario’s global reach and this Investing in technology and processes to reduce translation times, we can help improve patient access and reduce trial preparation times overall.”
* Employing new technologies to reduce the time it takes a translation provider to communicate with Clario
* Reduce the tedious processes associated with taking accurate screenshots and translating appropriate screens in eCOA applications
* Reduce defects and reduce human error by investing in automation and a new data-centric platform
Clients need reliable translation services to conduct studies in multiple countries and reach a diverse group of patients. However, they often encounter delays and technical issues. The main focus of the investment is to reduce the number of manual steps that are often required in the technical and complex process of producing accurate translations. Clario’s new translation workbench technology has been developed and released to directly address these issues.
For nearly 50 years, Clario has provided leading edge technology solutions for clinical trials. With experience gained from more than 19,000 clinical trials that have supported 870 regulatory accreditations, Clario brings together scientific expertise and global scope in the most comprehensive endpoint technology platform that empowers partners in the pharmaceutical, biotechnology and medical device industries to transform lives. Clario’s Trial Anywhere™ solutions have supported hybrid and decentralized clinical trials (DCT) for more than 15 years, enabling sponsors to collect high-quality endpoint data from any method or location while improving patient experience. Clario has 30 locations in nine countries in North America, Europe, and Asia Pacific.
“Certified tv guru. Reader. Professional writer. Avid introvert. Extreme pop culture buff.”